Oramed Pharmaceuticals Inc. (ORMP) stock
ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.71−0.32 (-7.94%)
Close on Nov 13, 2026Market cap $154.33MP/E 1.1Yield 6.74%
Oramed Pharmaceuticals EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Oramed Pharmaceuticals's EPS for the twelve months ending Sep 30, 2026 was $3.41, up 241.0% year over year. For fiscal 2025 it was $1.50. Over ten years it grew 9.2% a year on average. The highest annual figure on record is $1.50 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.50 | – |
| FY2024 | Dec 31, 2024 | -$0.48 | -442.9% |
| FY2023 | Dec 31, 2023 | $0.14 | -82.1% |
| FY2021 | Aug 31, 2021 | $0.78 | +39.3% |
| FY2020 | Aug 31, 2020 | $0.56 | -31.7% |
| FY2019 | Aug 31, 2019 | $0.82 | -4.7% |
| FY2018 | Aug 31, 2018 | $0.86 | +8.9% |
| FY2017 | Aug 31, 2017 | $0.79 | -9.2% |
| FY2016 | Aug 31, 2016 | $0.87 | +29.9% |
| FY2015 | Aug 31, 2015 | $0.67 | +8.1% |
| FY2014 | Aug 31, 2014 | $0.62 | +5.1% |
| FY2013 | Aug 31, 2013 | $0.59 | +3.5% |
| FY2012 | Aug 31, 2012 | $0.57 | – |
| FY2011 | Aug 31, 2011 | -$0.24 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $0.43 | -61.9% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $1.84 | +493.5% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $0.91 | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $0.23 | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $1.13 | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $0.31 | +40.9% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$0.19 | -575.0% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$0.25 | -180.6% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$0.48 | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $0.22 | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $0.04 | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $0.31 | +82.4% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$0.08 | -147.1% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$0.03 | -113.0% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$0.08 | -180.0% |
| Q3 FY2021CQ2 2021 | May 31, 2021 | $0.17 | -19.0% |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | $0.17 | +13.3% |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | $0.23 | – |
| Q3 FY2020CQ2 2020 | May 31, 2020 | $0.10 | -56.5% |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | $0.21 | -30.0% |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | $0.15 | -25.0% |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | -$1.51 | -938.9% |
| Q3 FY2019CQ2 2019 | May 31, 2019 | $0.23 | +53.3% |
| Q3 FY2018CQ2 2018 | May 31, 2018 | $0.30 | +25.0% |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | $0.20 | 0.0% |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | $0.18 | +20.0% |
| Q3 FY2017CQ2 2017 | May 31, 2017 | $0.15 | +7.1% |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | $0.24 | +14.3% |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | $0.20 | +33.3% |
| Q3 FY2016CQ2 2016 | May 31, 2016 | $0.15 | – |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | $0.14 | – |
| Q1 FY2016CQ4 2015 | Nov 30, 2015 | $0.21 | – |
| Q3 FY2015CQ2 2015 | May 31, 2015 | $0.15 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?